Jamie Renbarger, M.D., M.S.

Jamie Renbarger, M.D., M.S.

Caroline Symmes Scholar in Pediatric Cancer Research
Section Chief, Pediatric Hematology/Oncology
Adjunct Associate Professor of Medicine (Clinical Pharmacology) and Obstetrics and Gynecology
Interim Director, Indiana Institute for Personalized Medicine
Associate Professor of Pediatrics and Medicine

Phone: 317-944-8784
Email: jarenbar@iu.edu
705 Riley Hospital Drive, ROC 4340
Indianapolis, IN 46202



Pediatric Hematology Oncology

Areas of Interest

My primary research interest as a pediatric oncologist/stem cell transplant physician is in personalized medicine and pharmacogenomics in the treatment of childhood cancers.


My career path has been driven by my passion for taking care of patients, developing relationships, and teaching. During my initial pediatric rotation as a third year medical student, I found that I loved caring for children because of their resiliency and innocence. I was also attracted to pediatrics because of the multitude of academic opportunities in the field. Early in my residency, I developed a passion for pediatric hematology/oncology as well as pediatric critical care, attracted by the medical and psychosocial intensities of both fields. Within pediatric hematology/oncology, I was particularly drawn to the clinical care of pediatric hematopoietic stem cell transplant patients and ultimately chose this over critical care due to the opportunity to develop long-term relationships with patients and their families who we have the privilege to see for many years. I embarked upon my pediatric hematology/oncology fellowship training at Baylor College of Medicine with an open mind and an interest in getting good research experience as a foundation for my future academic career. I have always enjoyed thinking about medications, their mechanisms of action, and variability in both response and side effects. As such I decided to join the cancer pharmacology group for my fellowship research. I became passionate about developing ways to predict response to specific therapies we use in children with cancer and, in particular, understanding inter-individual variability in responses and toxicities. My hope is that my passion and research will lead to a better understanding on how to best treat individual children with cancer where the ultimate, initial goal is disease cure rather than control of symptoms. I feel privileged to come to work and think about ways to improve our approaches to caring for our patients.


1988-1992 B.S. in Chemistry, Cum Laude University of Rochester
1992-1996 M.D, St. Louis University School of Medicine
1996-1999 Pediatric Intern and Resident St. Louis University School of Medicine Cardinal Glennon Children's Hospital
1999-2002 Fellow, Pediatric Hematology-Oncology Baylor College of Medicine
2001-2002 Certificate, Clinical Investigation Baylor College of Medicine
2002-2003 Fellow, Clinical Pharmacology Indiana University School of Medicine
2002-2007 M.S., Clinical Investigation Indiana University

Honors & Awards

  • 1999-2000 Houston Junior League Texas Children’s Cancer Center Fellow, Baylor College of Medicine
  • 2003-2014 NIH Loan Repayment Program for Pediatric Research
  • 2007-2008 Elwert Award in Research, Indiana University School of Medicine
  • 2010 IUPUI Student Supervisor of the Year Award
  • 2011 2010 Presidential Early Career Award for Scientists and Engineers (PECASE)
  • 2013 St. Louis University School of Medicine, Pediatric Science Days Visiting Professor
  • 2013 Alpha Omega Alpha


Riley Outpatient Center
705 Riley Hospital Drive
Indianapolis, IN 46202
317-944-2143 phone
317-944-3107 fax

Research & Grants

My primary research interest as a pediatric oncologist/stem cell transplant physician is in personalized medicine and pharmacogenomics in the treatment of childhood cancers. Our work involves a major effort to identify biomarkers of drug toxicity and efficacy in the treatment of pediatric cancers. The ultimate goal is to use these biomarkers to develop simple, robust and practical clinical predictors of response to medications in individual patients that can be used to optimize dosing in the treatment of children, many of whom have curable malignancies.  I have extensive clinical and translational research experience involving an investigation of biomarkers in a variety of pediatric populations. As a pediatrician trained in both pediatric hematology/oncology and clinical pharmacology, I also serve as Associate Director of the Indiana Institute for Personalized Medicine. I am co-principal investigator of the Indiana HSCT Biobank (co-PIs S. Paczesny and J. Renbarger; R01HD074587, 8/2013 to 4/2018), a longitudinal clinic-biologic repository of de-identified samples linked to relevant clinical information. I am principal investigator on a pharmacology focused R01 (HD062484, 01/2011-12/2016) as well as our Indiana Center for Pediatric Pharmacology, both funded by NICHD (U54 HD071598, 9/2011-6/2016). This work has allowed me to establish myself as a national expert in personalized therapeutics for children and pharmacogenetics of chemotherapy induced peripheral neuropathy. I am the PI of our pediatric and developmental pharmacology T32 (HD069047, PIs Renbarger & Flockhart) as well as the Recruiting Officer for the Institutional K12 Grant (K12 HD068371; 2/2013-11/2018). I am also a key investigator on our Obstetric/Fetal Pharmacology Research Unit (U10 HD063094) for which I serve as the Director of Child Health Research

Feb 2010-Dec 2014 Indiana PREGMED (Maternal-Fetal Pharmacology Network Grant)
Co-investigator U10 HD063094-03

Jan 2011-Dec 2017 Pharmacogenetic Determinants of Vincristine Toxicity and Response
Principal Investigator
R01 HD062484-02

Sept 2011-Aug 2016 Indiana Center for Pediatric Pharmacology
Principal Investigator

July 2013-June 2018 Bridging Pediatric and Adult Biomarkers of Graft-Versus-Host-Disease
Co-Principal Investigator (Renbarger/Paczesny)

May 2011-April 2016 Indiana Pediatric Pharmacology Training Program
Principal Investigator
T32 HD069047-02



Topletz AR, Dennison JB, Barbuch RJ, Hadden CE, Hall SD, Renbarger JL. The Relative Contributions of CYP3A4 and CYP3A5 to the Metabolism of Vinorelbine. Drug Metab Dispos. 2013 Sep;41(9):1651-61.

Smith EM, Li L, Hutchinson RJ, Ho R, Burnette WB, Wells E, Bridges C, Renbarger J. Measuring Vincristine-Induced Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia. Cancer Nurs. 2013 Sep-Oct;36(5):E49-60. [Epub ahead of print] PMID: 23842524.

Lehmann AS, Renbarger JL, McCormick CL, Topletz AR, Rouse C, Haas DM. Pharmacogenetic predictors of nausea and vomiting of pregnancy severity and response to antiemetic therapy: a pilot study. BMC Pregnancy Childbirth. 2013 Jun 20;13(1):132. [Epub ahead of print] PMID: 23786674

Nalepa G, Barnholtz-Sloan J, Enzor R, Dey D, He Y, Gehlhausen JR, Lehmann AS, Park SJ, Yang Y, Yang X, Chen S, Guan X, Chen Y, Renbarger J, Yang FC, Parada LF, Clapp W. The tumor suppressor CDKN3 controls mitosis. J Cell Biol. 2013 Jun 24;201(7):997-1012. doi: 10.1083/jcb.201205125. Epub 2013 Jun 17. PMID: 23775190.

Costantine MM, Cleary K; Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric--Fetal Pharmacology Research Units Network. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstet Gynecol. 2013 Feb;121(2 Pt 1):349-53. PMID: 23344286

Haas DM, Quinney SK, Clay JM, Renbarger JL, Hebert MF, Clark S, Umans JG, Caritis SN; for the Obstetric-Fetal Pharmacology Research Units Network. Nifedipine Pharmacokinetics Are Influenced by CYP3A5 Genotype When Used as a Preterm Labor Tocolytic. Am J Perinatol. 2012 Aug 8. [Epub ahead of print]. PMID: 22875663

Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. Pediatr Blood Cancer. 2012 Jul 15; 59(1):144-8. PMID: 22431292.

Haas DM, Quinney SK, McCormick CL, Jones DR, Renbarger JL. A pilot study of the impact of genotype on nifedipine pharmacokinetics when used as a tocolytic. J Matern Fetal Neonatal Med. 2011 Jun 7. Epub ahead of print. PMID: 21644845

Langholz B, Skolnik J, Barrett J, Renbarger J, Seibel N, Zajicek A, Arndt C. Dactinomycin and vincristine toxicity in the treatment of childhood cancer: A retrospective study from the Children’s Oncology Group. Pediatr Blood Cancer. 2011 Aug;57(2):252-7. 2010 Dec 1. Epub ahead of print. PMID: 21125614.

Lehmann AS, Haas DM, McCormick CL, Skaar TC, Renbarger JL. Collection of human genomic DNA from neonates: a comparison between umbilical cord blood and buccal swabs. Am J Obstet Gynecol. 2011 Apr;204(4):362.e1-6. Epub 2011 Feb 16. PMID: 21324432.